

EDAP TMS

35 years of innovation in Minimally-invasive Therapies



Global leader in therapeutic ultrasound and active in the market for more than 35 years, EDAP TMS (NASDAQ: EDAP) develops, manufactures, promotes and distributes minimally-invasive medical devices for urology using ultrasound technology.

To maintain and strengthen its level of innovation and research, EDAP TMS annually invests 10% of its revenues in Research & Development activities (R&D).

EDAP TMS minimally-invasive therapies are now recognized around the world. The company is actively operating worldwide via an extensive network of corporate offices, subsidiaries and distribution partners: 85% of its business is exported worldwide. Relying on its global distribution network, the company targets the most dynamic markets (Asia, Americas and more recently Middle East), its range of lithotripters has registered a 50% growth over the past five years. Recently established in the USA, its products are either approved by the FDA (Sonolith® i-sys and Sonolith® i-move lithotripters) or pending FDA approval (Ablatherm® HIFU) for prostate cancer.

By constantly investing in Research & Development and partnering with internationally renowned medical research institutions, EDAP TMS has developed a strong valuable patent portfolio based on its innovative technologies.

EDAP TMS France

4 rue du Dauphiné - 69120 Vaulx en Velin - France

2013 Revenue: 18M€

Headquarter workforce: 91 employees

President: Marc Oczachowski

General Manager: Eric Soyser

EDAP TMS (Consolidated Group)

Registration year: 1979

NASDAQ: EDAP

2013 Group revenues: 24.1M€

% of revenues from exports : 85%


% of revenues invested in R&D: 10%

Number of patents applications: 400 +

Number of patents granted: 102

Group workforce: 150 employees

EDAP TMS worldwide



The Tradition of Innovation

For 35 years, EDAP TMS has been committed to introducing new and innovative technologies using a minimally-invasive approach in the treatment of urological disorders.

1979 EDAP TMS foundation

1985 Invention of the Piezo-electric shockwave technology for Extracorporeal Lithotripsy

1993 Ablatherm® HIFU is used for the first prostate cancer treatment on human (prototype device).

1997 Invention of the Electroconductive technology for Extracorporeal lithotripsy.

2000 Ablatherm® HIFU receives the CE mark and industrial production starts.

2005 Ablatherm® HIFU Integrated Imaging is launched (2nd generation machine of HIFU device marketed).

2007 Launch of Sonolith® i-sys, upmarket lithotripter (7th generation of Sonolith® lithotripters).

2010 Launch of Sonolith® i-move, modular lithotripter (8th generation of Sonolith® lithotripters).

2013 Launch of Focal One® HIFU device

EDAP TMS worldwide:

USA subsidiary - Austin, Texas

German subsidiary - Flensburg

Italian subsidiary - Roma

Japanese subsidiary - Tokyo

Malaysian subsidiary - Kuala Lumpur

South Korean representative office - Seoul

UAE representative office - Dubai

Russian representative office - Moscow

A partnership focused on innovation



EDAP TMS

2 Product ranges for two distinct therapeutic applications

HIFU - Prostate cancer

Non-invasive treatment of prostate cancer using High Intensity Focused Ultrasound (HIFU)

- More than **300 HIFU centers** in the world

ESWL - Urinary stones

Urinary stones treatment by electroconductive Extracorporeal Shockwave Lithotripsy (ESWL)

- More than **600 ESWL systems** installed in the world



Focal One®

Robot-assisted prostate tumorectomy
Launch: 2013

World first device dedicated to focal therapy of prostate cancer. Combined latest technologies in diagnostic (elastic fusion with MRI), therapy (new probe with exclusive dynamic focusing HIFU technology) and treatment control (contrast ultrasound) to target only the carcinogen area to be treated.

Ablatherm® HIFU

Non-invasive therapy for localized prostate cancer
Launch: 2005



The device uses High Intensity Focused Ultrasound to create a clear and irreversible necrosis of the targeted prostate cancer tissue while preserving the surrounding tissues.



Sonolith® i-move

The new generation of modular lithotripter
Launch: 2010

Modular mobile device that meets the needs of smaller health facilities (private hospitals). It can also be shared by different medical institutions through a mobile service (operated by EDAP TMS in France and in some countries, or even its partners).

Sonolith® i-sys

Integrated lithotripter
Launch: 2007



Genuine high-end platform intended for lithotripsy and endo-urological procedures in large clinical centers. It is marked out by its technological developments in shockwave generation that makes stone fragmentation power higher than competitors.